title: Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.
abstract: A patient with an FSH secreting pituitary adenoma is reported. Elevated FSH and serum free alpha-subunit (SU) with low levels of LH and testosterone (T) were found. Immunostaining showed the presence of alpha-SU, FSH-beta and LH-beta subunits. LHRH analogue (buserelin) was administered in a pulsatile manner, by portable computerized infusion pump sc for ten days. During the first 24 h of treatment FSH, LH (p less than 0.001) and T (p less than 0.01) rose significantly. Ten days later, the expected desensitization phenomenon did not occur, but further increases of T (8.4 +/- 2.6, mean +/- SD, vs 17.4 +/- 4.1 nmol/l, p less than 0.001) and FSH (58.9 +/- 9.6 vs 70.7 +/- 3.8 mlU/ml, p less than 0.001) were registered. LH decreased (12.5 +/- 2.4 vs 7.1 +/- 0.6 mlU/ml, p less than 0.001) at day 10, but remained higher than basal level (5.0 +/- 0.6, p less than 0.001). Free alpha-SU also rose (2.8 +/- 0.4 vs 4.4 +/- 1.7 mlU/ml, p less than 0.001) after ten days of treatment. The chronic stimulatory effect of analogue on LH with a lack of desensitization suggests tumorous secretion despite a partially preserved negative feedback of testosterone. Low basal LH levels, in some patients with FSH secreting tumors may not be due to tumor mass effect, but rather may be the consequence of altered LH production and/or secretion by the tumor. Although buserelin may not have a therapeutic effect, it is of use in differential diagnosis of hypergonadotropinemia.
authors.affiliation: University Clinical Center, Institute of Endocrinology, Diabetes and Metabolic Diseases, Beograd, Yugoslavia.
authors.forename: S
authors.initials: S
authors.lastname: Damjanović
authors.forename: D
authors.initials: D
authors.lastname: Micić
authors.forename: V
authors.initials: V
authors.lastname: Popović
authors.forename: M
authors.initials: M
authors.lastname: Petakov
authors.forename: A
authors.initials: A
authors.lastname: Kendereski
authors.forename: M
authors.initials: M
authors.lastname: Sumarac
authors.forename: D
authors.initials: D
authors.lastname: Manojlović
authors.forename: J
authors.initials: J
authors.lastname: Mićić
mesh_terms: D000238:Adenoma, Chromophobe / Q000097:blood* / Q000188:drug therapy*; D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood*; D015292:Glycoprotein Hormones, alpha Subunit / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
chemical_list: D015292:Glycoprotein Hormones, alpha Subunit; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin